Rosetta Genomics (NASDAQ:ROSG) today announced an update regarding their colon cancer diagnostic program and said that Ayelet Chajut, Executive Vice President, R&D, Head of Molecular Biology will speak more about this program at the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS-VI). The conference will held from November 9 to November 11 in Hong Kong where they will present a new generation of molecular diagnostic markers that will help in the treatment and diagnosis of colon cancer. Rosetta Genomics is one of the leading molecular diagnostics companies that develops and commercializes molecular diagnostic products based on its proprietary microRNAs. The company is also developing and discovering early detection cancer screening products, including a colon cancer screening test.
http://www.favstocks.com/rosetta-genomic... Rosetta Genomics have their labs in Philadelphia where they perform commercial molecular diagnostics tests in order to discover and develop new diagnostics markers.